Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 10 April 2017, 11:23 HKT/SGT

Source: Hitachi, Ltd.
Hitachi is selected by Sumitomo Dainippon Pharma for Automated Cell Mass Culture Equipment for Regenerative Medicine using Human iPS Cells
Research equipment for the manufacturing cells used in Parkinson's disease treatment

TOKYO, Apr 10, 2017 - (JCN Newswire) - Hitachi, Ltd. announced today that Hitachi has received an order for automated cell mass culture equipment for regenerative medicine using human iPS cells from Sumitomo Dainippon Pharma Co., Ltd.

This equipment adopts a closed flow channel(1) with excellent sterility and reduces pathogen and microbial contamination from the external environment. Sumitomo Dainippon Pharma addresses practical uses of allogeneic iPS cell(2)-derived dopaminergic neural progenitor cells(3) with which treat Parkinson's disease(4) caused by dopamine neuron loss and neurodegeneration with Center for iPS Cell Research and Application, Kyoto University (CiRA). Hitachi contributes to the research of Sumitomo Dainippon Pharma to make dopaminergic neural progenitor cells practical use by offering this equipment. Furthermore, Hitachi and Sumitomo Dainippon Pharma have been a joint research within the framework of the "Project Focused on Developing Key Evaluation Technology: Evaluation for Industrialization in the Field of Regenerative Medicine", awarded by Japan Agency of Medical Research and Development (AMED) with a view to evaluating validity of processing methods adjusted for practical use of the automatic cell culture equipment which aims at the clinical treatment of patients with Parkinson's disease by using human iPS cells.

The iPS cells, called pluripotent stem cells, are able to develop into many types of tissues and organs, so they are expected to repair wounded cells as the regenerative medicine. An investigator-led clinical trial of an ocular disease using the iPS cells was conducted for the first time in Japan in 2014. Moreover, promoting commercialization of the regenerative medicine was enforced in November 2014. Therefore, the market size of the regenerative medicine in Japan was predicted to expand, and the market size including the regenerative medicine-related industries will be about 190 billion yen(5) in 2020 and be about 3,800 billion yen(5) in 2050. On the other hand, resolutions of many technical challenges are needed so that regenerative medicine using human iPS cells will be popular. Especially, automation of manufacturing processes done by mostly hand and a supply of high quality cells at reasonable price are essential.

Sumitomo Dainippon Pharma has been undertaken the research in the field of regenerative medicine since the 1980s, and is conducting the research using the iPS cells in order to overcome incurable diseases such as Parkinson's disease, age-related macular degeneration (AMD)(6), retinitis pigmentosa(7) and spinal cord injury in cooperation with venture companies, universities and research institutes at present.

Hitachi has delivered not only pharmaceutical plants but also regenerative medicine plants including cell processing facilities, biosafety cabinets for manufacturing and manufacturing execution system (MES) to pharmaceuticals.

Moreover, Hitachi has provided clinical blood analyzers and sample preparation system for medical institutions, and develop inspection systems in the process of manufacturing medicine for the pharmaceuticals. Furthermore, Hitachi has been developing the automated cell culture technology through participation in national projects(8) and The techonolgy that are developed at the project is applied to this equipment.

The automated cell culture equipment at this order consists of single-use consumables such as bottles, tubes and cell culture dishes. It cultures and differentiates the iPS cells efficiently because it can manufacture large amounts of the cells automatically and observe the cells under the closed sterile environment.

Hitachi will meet various kinds of needs from the customers in the regenerative medicine market, and promotes the development and the sale from now on, and then contributes to the progress of healthcare.

(1) a closed flow channel: replace cell culture medium in the cell culture dishes under the closed sterile environment in order to avoid pathogen and microbial contamination from the external environment
(2) allogeneic iPS cells: cells aren't from patient's own (autologous) cultured cells but from someone else's (allogeneic) cultured cells
(3) dopaminergic neural progenitor cells: progenitor cells can be differentiated to dopaminergic neurons which release dopamine as a neurotransmitter
(4) Parkinson's disease: a neurodegenerative disorder caused by dopamine neuron loss and neurodegeneration that affects body movements
(5) Source: Ministry of Economy, Trade and Industry "Final Report Compiled by the Study Group on Commercialization and Industrialization of Regenerative Medicine" in 2013
(6) age-related macular degeneration (AMD): macular degeneration with aging weakens eyesight
(7) retinitis pigmentosa: degeneration of rod photoreceptor cells in a retina weakens eyesight
(8) New Energy and Industrial Technology Development Organization (NEDO), "Basic Technologies Research Promotion Project", Cabinet Office, Government of Japan, "Funding Program for World-Leading Innovative R&D on Science and Technology(FIRST)", Ministry of Education, Culture, Sports, Science and Technology, "Creation of Innovation Centers for Advanced Interdisciplinary Research Areas Program"

About Hitachi, Ltd.

Hitachi, Ltd. (TSE: 6501), headquartered in Tokyo, Japan, delivers innovations that answer society's challenges with our talented team and proven experience in global markets. The company's consolidated revenues for fiscal 2014 (ended March 31, 2015) totaled 9,761 billion yen ($81.3 billion). Hitachi is focusing more than ever on the Social Innovation Business, which includes power & infrastructure systems, information & telecommunication systems, construction machinery, high functional materials & components, automotive systems, healthcare and others. For more information on Hitachi, please visit the company's website at

Hitachi Ltd
Corporate Communications
Tel: +81-3-3258-1111

Apr 10, 2017 11:23 HKT/SGT
Source: Hitachi, Ltd.

Hitachi, Ltd. (TSE: 6501)

Topic: Press release summary
Sectors: BioTech
From the Asia Corporate News Network

Copyright © 2017 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Hitachi, Ltd.
Dec 15, 2017 13:38 HKT/SGT
Hitachi to Install New Proton Beam Therapy System in Spain
Dec 15, 2017 09:59 HKT/SGT
UK ABWR Successfully Completes GDA Process
Dec 14, 2017 11:39 HKT/SGT
Hitachi Promotes ASEAN Business Strategy at Board of Directors Meeting in Singapore
Dec 14, 2017 11:03 HKT/SGT
Partners Connected Health and Hitachi Develop an Explainable Ai Technology to Help Doctors Predict Readmissions and Improve Patient Outcomes
Dec 11, 2017 13:22 HKT/SGT
Hitachi Invests in Preferred Networks
Dec 8, 2017 10:47 HKT/SGT
Hitachi and Mitsubishi Electric Agree to Integrate Particle Therapy System Business
Dec 6, 2017 12:05 HKT/SGT
Hitachi: Successful Observation of a Magnetic Field With the World's Highest Resolution of 0.67nm Using an Atomic-Resolution Holography Electron Microscope
Nov 29, 2017 12:00 HKT/SGT
Hitachi's Setting Goals to Promote Diversity
Nov 29, 2017 11:46 HKT/SGT
Hitachi Builds New Global Integrated Platform to Promote Greater Participation by the Group's Diverse Employees
Nov 15, 2017 08:13 HKT/SGT
Hitachi Develops Open Source Software Based Big Data Analytics Technology to Increase Speed by Up to 100 Times
More news >>
 News Alerts
Copyright © 2017 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: